Lacosamide Sandoz (Lacosamide)

Lacosamide is an anti‑epileptic drug used as adjunctive therapy for focal seizure disorders.

• Partial‑onset (focal) seizures: Reduces seizure frequency when added to existing antiepileptic therapy.
• Focal seizures with secondary generalization: Helps control seizure spread in patients with refractory epilepsy.
• Adjunctive therapy in epilepsy: Improves overall seizure management for patients not adequately controlled by monotherapy.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing neuronal membranes and reducing repetitive neuronal firing. It also binds to collapsin response mediator protein‑2 (CRMP‑2), a protein involved in neuronal development and axonal guidance, thereby modulating neuronal excitability and contributing to its anticonvulsant effect.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Dizziness: Light‑headed sensation, often occurring at treatment initiation.
• Headache: Mild to moderate intensity, usually transient.
• Nausea: Gastrointestinal discomfort that may improve with continued use.
• Fatigue: Generalized tiredness or reduced energy levels.

Serious or Rare Side Effects

• Cardiac conduction abnormalities: PR‑interval prolongation that can lead to arrhythmias.
• Suicidal thoughts or behavior: Emergence of depressive symptoms or suicidal ideation.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis, requiring immediate medical attention.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Renal impairment: Adjust dose if severe kidney dysfunction is present.
• Hepatic impairment: Use with caution in patients with liver disease.
• Cardiac conduction: Monitor ECG for PR‑interval prolongation.
• Concomitant antiepileptic drugs: Assess for additive CNS depression.
• Pregnancy and lactation: Use only if benefit outweighs risk.
• Store at ambient temperature: Keep below 25 °C, protect from moisture and light in original packaging.

Lacosamide can interact with several medicines, requiring careful assessment.

Major Interactions (Avoid)

• Concomitant use with strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): May reduce lacosamide plasma levels.
• Co‑administration with other sodium channel blockers (e.g., lamotrigine, oxcarbazepine): Increases risk of CNS depression.
• Combination with drugs that prolong PR interval (e.g., verapamil): May cause cardiac conduction abnormalities.

Moderate Interactions (Monitor Closely)

• Use with other antiepileptic drugs (e.g., valproate, topiramate): May require dose adjustments.
• Concurrent use of alcohol or CNS depressants: May enhance dizziness and sedation.
• Interaction with anticoagulants (e.g., warfarin): Monitor INR as lacosamide may affect bleeding risk.